

# THE LANCET Oncology

## Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Aebi S, Gelber S, Anderson SJ, et al, on behalf of the CALOR investigators. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. *Lancet Oncol* 2014; published online January 16. [http://dx.doi.org/10.1016/S1470-2045\(13\)70589-8](http://dx.doi.org/10.1016/S1470-2045(13)70589-8).

# **SUPPLEMENTARY MATERIAL to Aebi et al., Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial**

## **Section 1: CALOR Collaborative Group Participants**

Steering Committee: S. Aebi (Study Co-Chair), I. L. Wapnir (Study Co-Chair), S. J. Anderson, A.S. Coates, M. Colleoni, R.D. Gelber, S. Gelber, C. E. Geyer, Jr., A. Hiltbrunner, R. Maibach, M. Martin, J.W.R. Nortier, K.N. Price, P. Rastogi, A. Robidoux.

IBCSG Foundation Council: R. Stahel (President), S. Aebi, A. S. Coates, M. Colleoni, R. D. Gelber, A. Goldhirsch, M. Green, P. Karlsson, I Kössler, I. Láng.

IBCSG Coordinating Center, Bern, Switzerland: A. Hiltbrunner (Director), R. Kammler, R. Maibach, M. Rabaglio, B. Ruepp, P. Sicher, S. Roux.

IBCSG Statistical Center, Dana-Farber Cancer Institute, Boston, MA, USA: R.D. Gelber (Director), M.M. Regan (Group Statistician), K.N. Price, S. Gelber.

IBCSG Data Management Center, Frontier Science & Technology Research Foundation, Amherst, NY, USA: L. Blacher (Director), T. Heckman-Scolese, K. Scott, J. Celano.

### ***Breast International Group (BIG) (Accrued: 89)***

#### **International Breast Cancer Study Group (IBCSG) (Accrued: 57)**

Hungary: National Institute of Oncology, Budapest: I. Láng, E. Hitre, E. Szabó, Z. Horváth, E. Ganofszy, E. Juhos. (Accrued: 33)

South Africa: Groote Schuur Hospital and University of Cape Town: E. Murray (Accrued: 5)

Switzerland: Swiss Group for Clinical Cancer Research (SAKK) (Accrued: 16): Inselspital, Berne: M. Rabaglio, S. Aebi, M. F. Fey, M. Castiglione/ Kantonsspital Olten, Olten: S. Aebi, M. F. Fey, M. Zuber, G. Beck/ Bürgerspital, Solothurn (Accrued:6): S. Aebi, M. F. Fey, R. Schönenberger; Spital STS AG (Accrued: 2), Thun: J.M. Lüthi, D. Rauch; Kantonsspital St. Gallen (Accrued: 5), St. Gallen: B. Thürlimann, T. Ruhstaller, L. Vor Rohr, J. Müller, C. Öhlschlegel, U. Hasler, M. Früh, J. Kehl-Blank, E. Vogel; Zürich Frauenklinik (Accrued:3): D. Fink

Australia: Australia and New Zealand Breast Cancer Trials Group (ANZBCTG): J.F Forbes, N. Wilcken, F. Boyle, H.Badger. Peter MacCallum Cancer Centre, Melbourne, Victoria: R. Jennens, P. Francis, Flinders Medical Centre, Bedford Park, South Australia: C. Karapetis, B. Koczwara (Accrued: 2)

Peru: Instituto de Enfermedades Neoplásicas, Lima: H. Gome. (Accrued: 1)

#### **Grupo Español de Investigación en Cáncer de Mama (GEICAM) (Accrued: 20)**

Spain: Hospital Universitario San Carlos (Accrued: 5), Madrid: M. Martin, Hospital Puerta Del Mar (Accrued: 6), Cádiz: J.M. Baena Cañada, Universitario Virgen de la Victoria (Accrued: 3), Emilio Alba Conejo, Málaga, Fundación Alcorcón (Accrued: 2), Madrid: C. Jara. Clínico Valencia (Accrued: 4), Valencia: A. Lluch

#### **Dutch Breast Cancer Trialists' Group (BOOG) (Accrued: 12)**

The Netherlands: Leids Universitair Medisch Centrum (Accrued: 5), Leiden: J.W.R. Nortier, Isala Klinieken (Accrued: 2), Zwolle: A.H. Honkoop, Ziekenhuis Rijnstate Arti (Accrued: 2), Ziekenhuis: J. Douma, University Hospital Maastricht (Accrued: 1), Maastricht: V.C.G. Tjan-Heijnen, University Hospital Nijmegen (Accrued: 1), Nijmegen: P. Ottevanger, Medical Center Leeuwarden (Accrued: 1), Leeuwarden: H. De Graaf

#### ***National Surgical Adjuvant Breast and Bowel Project (NSABP) (Accrued: 73)***

**NSABP Coordinating Center:** W. Cronin, M.J. Antonelli, M. Passarello, C.E. Geyer, Jr.

Canada: University of Montreal Hospital Group, Montreal, Quebec: A. Robidoux (Accrued: 16), Tom Baker Cancer Centre, Calgary, Alberta: A. Paterson (Accrued: 7), Jewish General Hospital, Montreal, Quebec: R. Margolese (Accrued: 2), Centre Hospitalier Affilie Universitaire de Quebec (CHA), Quebec City, Quebec: L. Provencher (Accrued: 2), Cross Cancer Institute, Edmonton, Alberta: K. King (Accrued: 2), Montreal General Hospital, Montreal, Quebec: M. Thirwell (Accrued: 1), Odette Cancer Centre, Toronto, Ontario: J-P Pignol (Accrued: 1)

United States of America: Baylor College of Medicine, Houston, TX: M. Rimawi (Accrued: 7), Stanford University, Palo Alto, CA: I. L. Wapnir (Accrued: 5), Cancer Trials Support Unit, Washington, DC: S. Riordan (Accrued 4), CCOP, Carle Cancer Center, Urbana, IL: K. Rowland (Accrued: 3), CCOP, Michigan Cancer Research Consortium, MI: P. Stella (Accrued: 2), Kaiser Permanente, Northern CA Region, Vallejo, CA: L. Fehrenbacher (Accrued: 2), University of Pittsburgh, PA: A. M. Brufsky (Accrued: 2), Wake Forest University School of Medicine, Winston-Salem, NC: E. Levine (Accrued: 2), Aultman Hospital, Canton, OH: S. Trehan (Accrued: 1), Baptist Regional Cancer Institute, Jacksonville, FL: T. Guthrie (Accrued: 1), Camden-Clark Memorial Hospital, Parkersburg, WV: N. Shah (Accrued: 1), Case Western Reserve University/University Hospitals of Cleveland, OH: R. Leeming (Accrued: 1), CCOP, Central Illinois, Springfield, IL: J. Wade (Accrued: 1), CCOP, Marshfield Clinic, Marshfield, WI: J. Wernberg (Accrued: 1), CCOP, S. NV Cancer Research Foundation, Las Vegas, NV: J. Ellerton (Accrued: 1), CCOP, Southeast Cancer Control Consortium, Winston-Salem, NC: J. N. Atkins (Accrued: 1), CCOP, Upstate Carolina, Spartanburg, SC: J. Bearden (Accrued: 1), Glens Falls Hospital, Glens Falls, NY: R. Sponzo (Accrued: 1), Joe Arrington Cancer Research & Treatment Center, Lubbock, TX: I. Shalaby (Accrued: 1), Lehigh Valley Hospital, Allentown, PA: L. C. Alfonse (Accrued: 1), University of Colorado Cancer Center, Denver, CO: N. Kounalakis (Accrued: 1), University of Kentucky, Lexington, KY: E. H. Romond (Accrued: 1), Western Pennsylvania Hospital, Pittsburgh, PA: J. Lech (Accrued: 1)

## Section 2. CALOR Supplementary Tables and Figures

**Table S1: Cross-tabulation of adjuvant chemotherapies used for primary breast cancer and for isolated locoregional recurrence (ILRR) (patients assigned to chemotherapy group)**

Chemotherapy Received for ILRR	Chemotherapy Received for Primary Tumor				Total
	No Chemotherapy received	CMF	Poly- anthracycline	Poly-taxane + anthracycline	
No Chemotherapy received – no. (%)	0	3 (4)	0	2 (2)	5 (6)
Monochemotherapy – no. (%)					
Docetaxel or paclitaxel	2 (2)	1 (1)	11 (13)	2 (2)	16 (19)
Capecitabine	1 (1)	0	1 (1)	7 (8)	9 (11)
Polychemotherapy – no. (%)					
CMF	0	0	2 (2)	0	2 (2)
Gemcitabine + navelbine	0	0	0	1 (1)	1 (1)
Anthracycline	31 (36)	5 (6)	1 (1)	1 (1)	38 (45)
Docetaxel or paclitaxel	1 (1)	2 (2)	8 (9)	2 (2)	13 (15)
Taxane + anthracycline	1 (1)	0	0	0	1 (1)
Total	36 (42)	11 (13)	23 (27)	15 (18)	85

CMF: Cyclophosphamide, methotrexate, fluorouracil

Anthracycline-based: Doxorubicin or epirubicin, cyclophosphamide; doxorubicin or epirubicin followed by CMF; doxorubicin or epirubicin, cyclophosphamide, fluorouracil; doxorubicin monotherapy

Taxane-based: Paclitaxel; docetaxel; non-anthracycline taxane-containing multidrug regimens.

Taxane+anthracycline: Any regimen incorporating an anthracycline and a taxane simultaneously or sequentially.

**Table S2. Serious Adverse Events (SAE) Reported to be Possibly, Probably, or Likely Related to Chemotherapy for the ILRR**

No. of patients with at least one SAE	12
No. of SAEs reported	16
Neutropenia	2
Febrile neutropenia	3
Intestinal infection	2
Abdominal pain	1
Respiratory/pulmonary infection	1
Cardiac ischemia, left ventricular dysfunction	3
Motor neuropathy	1
Generalized musculoskeletal pain	1
Severe fatigue	1
Thickening of endometrial mucosa	1

**Table S3. 5-year Disease-Free Survival (DFS) and Treatment Effects for 143 Patients with both Primary Tumor and ILRR ER Status Known**

ER status of 1° Cancer/ ILRR Treatment	Negative/Negative		Positive/Negative		Negative/Positive		Positive/Positive	
	CT	No CT	CT	No CT	CT	No CT	CT	No CT
No. of cases	21	20	7	8	6	0	42	39
No. of DFS events	6	11	1	6	3	0	13	15
5-year DFS (%)	68	44	83	19	50	*	67	65
Standard error (%)	11	11	15	16	20	*	9	8
Hazard ratio	0.37		0.15		*		0.93	
95% CI	0.14 to 1.01		0.02 to 1.27		*		0.44 to 1.96	

\* Cannot be calculated (0 events)